Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | FDPS | P14324 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | FABP1 | P07148 | 1/20 | 0.51 |
| ▸ | FABP6 | P51161 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 10/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenyramidol SCHEMBL13310227 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL13310219 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL21963 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL20769334 | 0.98 | CYP2D6 (0.97) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL29375712 | 0.98 | CYP2D6 (0.97) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL121004 | 0.98 | CYP2D6 (0.97) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL3446649 | 0.94 | CYP2D6 (0.88) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| SCHEMBL9566716 | 0.87 | CYP2D6 (0.77) | CYP2D6KDM4EFDPSFABP1FABP6 | |
| Phenyramidol SCHEMBL22718457 | 0.84 | CYP2D6 (0.71) | CYP2D6KDM4EFDPSFAAHAOC3 | |
| SCHEMBL4281005 | 0.84 | CYP2D6 (0.72) | CYP2D6KDM4EFDPSL3MBTL1FABP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024197124-A9 | ARGININE VASOPRESSIN RECEPTOR (AVPR) ANTAGONISTS AND METHODS OF USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024197124-A2 | ARGININE VASOPRESSIN RECEPTOR (AVPR) ANTAGONISTS AND METHODS OF USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20230398132-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | GREENWOOD BRANDS, LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11771708-B2 | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same | GREENWOOD BRANDS, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11648257-B2 | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same | PLX OPCO INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4157357-A1 | ANTIBODY-DRUG CONJUGATES | Spirea Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| US-11389453-B2 | Compositions and methods for treating chemosensory dysfunction | CYRANO THERAPEUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220168321-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | PLX OPCO INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | CYP2D6 322/4885KDM4E 3751/4885FDPS 4210/4885 |
| US-20220168321-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | ABCB11, SLC47A1, SLC46A1 | CYP2D6 200/4885KDM4E 4340/4885FDPS 610/4885 |
| US-20230398132-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | ABCB11, SLC47A1, SLC46A1 | CYP2D6 200/4885KDM4E 4340/4885FDPS 610/4885 |
| US-11648257-B2 | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same | ABCB11, SLC47A1, SLC46A1 | CYP2D6 200/4885KDM4E 4340/4885FDPS 610/4885 |
| US-11771708-B2 | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same | ABCB11, SLC47A1, SLC46A1 | CYP2D6 200/4885KDM4E 4340/4885FDPS 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.